Marco Casciaro, Michele Navarra, Giuseppina Inferrera, Marta Liotta, Sebastiano Gangemi, Paola Lucia Minciullo
{"title":"PPI adverse drugs reactions: a retrospective study.","authors":"Marco Casciaro, Michele Navarra, Giuseppina Inferrera, Marta Liotta, Sebastiano Gangemi, Paola Lucia Minciullo","doi":"10.1186/s12948-019-0104-4","DOIUrl":null,"url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) are drugs capable of blocking the gastric pump H,K-ATPase in order to inhibit gastric acid secretion. Omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole belong to PPIs category. Although PPIs have a good safety profile, allergic reactions to these molecules can occur. The real rate of hypersensitive reactions to PPIs is unknown. The aim of this retrospective study is to evaluate the rate of hypersensitive reactions to PPIs in patients admitted to our Unit between 2008 and 2013 with a history of drug hypersensitivity. From a database of 1229 patients (921 women, 308 men) with adverse drug reaction we extrapolated the data about PPI reactions. Twelve patients (10 female, 2 men) had a positive history for hypersensitive reaction to PPI. Pantoprazole was the most frequently PPI involved. Based on patient personal history in some cases we performed an oral challenge test for an alternative anti-acid drug and none of them had adverse reactions. According to our experience and according to the literature and pharmacovigilance reports, ADR caused by PPIs are ever increasing. Adverse reactions to these drugs are still under-reported; however, considering the frequency of their prescription worldwide, the risk of severe allergic events is low. Further studies are needed to provide clearer data on the real incidence and prevalence about this matter. This should be useful to help physician in choosing the molecule to prescribe and, in case of hypersensitivity, the alternative molecule to test, also considering the possible cross-reactivity.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"17 ","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-019-0104-4","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-019-0104-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 15
Abstract
Proton pump inhibitors (PPIs) are drugs capable of blocking the gastric pump H,K-ATPase in order to inhibit gastric acid secretion. Omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole belong to PPIs category. Although PPIs have a good safety profile, allergic reactions to these molecules can occur. The real rate of hypersensitive reactions to PPIs is unknown. The aim of this retrospective study is to evaluate the rate of hypersensitive reactions to PPIs in patients admitted to our Unit between 2008 and 2013 with a history of drug hypersensitivity. From a database of 1229 patients (921 women, 308 men) with adverse drug reaction we extrapolated the data about PPI reactions. Twelve patients (10 female, 2 men) had a positive history for hypersensitive reaction to PPI. Pantoprazole was the most frequently PPI involved. Based on patient personal history in some cases we performed an oral challenge test for an alternative anti-acid drug and none of them had adverse reactions. According to our experience and according to the literature and pharmacovigilance reports, ADR caused by PPIs are ever increasing. Adverse reactions to these drugs are still under-reported; however, considering the frequency of their prescription worldwide, the risk of severe allergic events is low. Further studies are needed to provide clearer data on the real incidence and prevalence about this matter. This should be useful to help physician in choosing the molecule to prescribe and, in case of hypersensitivity, the alternative molecule to test, also considering the possible cross-reactivity.
质子泵抑制剂(PPIs)是一种能够阻断胃泵H, k - atp酶以抑制胃酸分泌的药物。奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑和埃索美拉唑属于PPIs类。虽然PPIs具有良好的安全性,但对这些分子可能发生过敏反应。对PPIs过敏反应的真实比率尚不清楚。本回顾性研究的目的是评估2008年至2013年期间在我们科室就诊的有药物过敏史的患者对PPIs过敏反应的发生率。从1229例药物不良反应患者(921例女性,308例男性)的数据库中,我们推断出PPI反应的数据。12例患者(女10例,男2例)有PPI超敏反应阳性病史。泮托拉唑是最常见的PPI。根据患者的个人病史,在一些病例中,我们对一种替代抗酸药物进行了口服激发试验,没有任何不良反应。根据我们的经验,根据文献和药物警戒报告,ppi引起的不良反应不断增加。这些药物的不良反应仍未得到充分报道;然而,考虑到他们在世界范围内的处方频率,严重过敏事件的风险很低。需要进一步的研究来提供关于这一问题的真实发病率和流行率的更明确的数据。这应该有助于医生选择处方分子,并在过敏的情况下,考虑到可能的交叉反应,选择可供测试的替代分子。
期刊介绍:
Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.